He has received payment or honoraria from Fishawack, Integritas Communications, Kenes, Madrigal, Medscape, Novo Nordisk and Springer Healthcare
Peng X, Yang Y, Zhong R, et al
Share: A minimally invasive outpatient procedure may help people avoid regaining weight after stopping popular medications like Ozempic and semaglutide, according to research being presented at Digestive Disease Week (DDW) 2026
Its a triple agonist targeting: GLP-1 appetite suppression and blood sugar regulation GIP enhanced insulin response, additional satiety effects Glucagon this is new
No est solo: la nueva generacin oral Orforglipron encabeza una oleada cada vez ms amplia de nuevos candidatos orales desarrollados por distintas farmacuticas, reflejo del fuerte impulso por trasladar la eficacia de las terapias incretnicas a formulaciones no inyectables
Findings from NHANES 2017-2018